![OGSIVEO FDA-Approval Featured Image](https://dtrf.org/wp-content/uploads/2023/11/breaking-news-niro-FDA-approval-featured-image-2-720x450.png)
Featured News
FDA APPROVES OGSIVEO™ (NIROGACESTAT), AS THE FIRST MEDICAL THERAPY FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMORS.
Filter by:
![](https://dtrf.org/wp-content/uploads/2024/06/GCP_2024-720x450.png)
June 26, 2024
Updated Desmoid Tumor Treatment Guidelines, funded in part by DTRF, Published in JAMA Oncology
![](https://dtrf.org/wp-content/uploads/2024/06/asco_roundup_1200-x-800-720x450.jpg)
June 14, 2024
DTRF Executive Director Lynne Hernandez served as a faculty member this year at an educational session – 2024 Annual Meeting for the American Society of Clinical Oncology (ASCO)
![](https://dtrf.org/wp-content/uploads/2024/03/IG-Square-Posts_2024_DTRF-720x450.png)
March 19, 2024
Young Adult Virtual Event Series: “Times Are A-Changin’: Heading into Young Adulthood with a Desmoid Tumor.”
![OGSIVEO FDA-Approval Featured Image](https://dtrf.org/wp-content/uploads/2023/11/breaking-news-niro-FDA-approval-featured-image-2-720x450.png)
November 27, 2023
FDA APPROVES OGSIVEO™ (NIROGACESTAT), AS THE FIRST MEDICAL THERAPY FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMORS.
![Jeanne Whiting, DTRF Executive Director Emeritus, and Lynne Hernandez, DTRF Executive Director](https://dtrf.org/wp-content/uploads/2023/11/lynne-jeanne-pag-poster-100-720x450.jpg)
November 14, 2023
DTRF Leadership Team Attends CTOS 2023
![](https://dtrf.org/wp-content/uploads/2023/11/facebook-cover-dtrf-720x450.png)